NCT05755620
A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 73 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 19, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 56 words
- Primary endpoints: 9 to 8
- Secondary endpoints revised (6)
- Study arms: 5 to 4
- Minor Trial status: Active, Not Recruiting to Completed
- Primary and study completion dates changed from estimate of Dec 4, 2025 to Oct 3, 2025
- Minor Primary and study completion dates: Aug 20, 2025 to Dec 4, 2025v65
- Notable Enrollment target: 30 to 50v62
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 10 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 10 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 25 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 25 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
Experimental: Arm 3, High Dose 10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 50 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 50 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. The High Dose was selected as the optimal dose as it was the highest dose with no identified safety concerns by the Safety Review Committee (SRC). An additional 10 (optimal dose) participants were therefore enrolled into the High Dose group. Total N = 20
10 healthy adult volunteer subjects from 18-49 years of age will receive licensed Quadrivalent Influenza Vaccine (IIV4), administered intramuscularly once. Subjects receiving IIV4 will be followed for safety, but only their immune responses will be compared to those of participants receiving H1ssF\_3928 mRNA Vaccine. N=10
Biologicals: Influenza Virus Quadrivalent Inactivated Vaccine, VRC-FLUNPF099-00-VP (H1ssF_3928)
Other: Sodium Chloride, 0.9%
Sites
1 site in 1 country
- Duke Vaccine and Trials UnitDurham, North Carolina, United States